337 related articles for article (PubMed ID: 11304729)
1. High-grade prostate cancer is associated with low serum testosterone levels.
Schatzl G; Madersbacher S; Thurridl T; Waldmüller J; Kramer G; Haitel A; Marberger M
Prostate; 2001 Apr; 47(1):52-8. PubMed ID: 11304729
[TBL] [Abstract][Full Text] [Related]
2. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
3. Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer.
Schatzl G; Marberger M; Remzi M; Grösser P; Unterlechner J; Haidinger G; Zidek T; Preyer M; Micksche M; Gsur A
Urology; 2005 Jun; 65(6):1141-5. PubMed ID: 15893813
[TBL] [Abstract][Full Text] [Related]
4. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer.
Schatzl G; Madersbacher S; Haitel A; Gsur A; Preyer M; Haidinger G; Gassner C; Ochsner M; Marberger M
J Urol; 2003 Apr; 169(4):1312-5. PubMed ID: 12629350
[TBL] [Abstract][Full Text] [Related]
5. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
[TBL] [Abstract][Full Text] [Related]
6. Influence of radical prostatectomy on serum hormone levels.
Miller LR; Partin AW; Chan DW; Bruzek DJ; Dobs AS; Epstein JI; Walsh PC
J Urol; 1998 Aug; 160(2):449-53. PubMed ID: 9679896
[TBL] [Abstract][Full Text] [Related]
7. Absence of relationship between steroid hormone levels and prostate cancer tumor grade.
Sher DJ; Mantzoros C; Jacobus S; Regan MM; Lee GS; Oh WK
Urology; 2009 Feb; 73(2):356-61; discussion 361-2. PubMed ID: 19036418
[TBL] [Abstract][Full Text] [Related]
8. A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis.
Nam RK; Reeves JR; Toi A; Dulude H; Trachtenberg J; Emami M; Daigneault L; Panchal C; Sugar L; Jewett MA; Narod SA
J Urol; 2006 Apr; 175(4):1291-7. PubMed ID: 16515983
[TBL] [Abstract][Full Text] [Related]
9. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
10. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
11. Development of a nomogram for predicting high-grade prostate cancer on biopsy: the significance of serum testosterone levels.
Ide H; Yasuda M; Nishio K; Saito K; Isotani S; Kamiyama Y; Muto S; Horie S
Anticancer Res; 2008; 28(4C):2487-92. PubMed ID: 18751439
[TBL] [Abstract][Full Text] [Related]
12. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening.
Yano M; Imamoto T; Suzuki H; Fukasawa S; Kojima S; Komiya A; Naya Y; Ichikawa T
Eur Urol; 2007 Feb; 51(2):375-80. PubMed ID: 17005316
[TBL] [Abstract][Full Text] [Related]
13. Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu.
Takizawa I; Nishiyama T; Hara N; Isahaya E; Hoshii T; Takahashi K
Prostate; 2010 Sep; 70(13):1395-401. PubMed ID: 20687212
[TBL] [Abstract][Full Text] [Related]
14. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
16. Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients?
Imamoto T; Suzuki H; Yano M; Kawamura K; Kamiya N; Araki K; Komiya A; Naya Y; Shiraishi T; Ichikawa T
Prostate Cancer Prostatic Dis; 2009; 12(1):78-82. PubMed ID: 18521100
[TBL] [Abstract][Full Text] [Related]
17. Association of DHEA-S and estradiol serum levels to symptoms of aging men.
Ponholzer A; Plas E; Schatzl G; Jungwirth A; Madersbacher S;
Aging Male; 2002 Dec; 5(4):233-8. PubMed ID: 12630070
[TBL] [Abstract][Full Text] [Related]
18. Association between lower urinary tract symptoms and serum levels of sex hormones in men.
Miwa Y; Kaneda T; Yokoyama O
Urology; 2008 Sep; 72(3):552-5. PubMed ID: 18597822
[TBL] [Abstract][Full Text] [Related]
19. Investigative clinical study on prostate cancer part IX and X: estradiol and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy.
Porcaro AB; Ghimenton C; Petrozziello A; Sava T; Migliorini F; Romano M; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C
Anticancer Res; 2012 Oct; 32(10):4523-32. PubMed ID: 23060581
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV
Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]